ASCO Preview: Elotuzumab’s ‘Double Whammy’ Mechanism Hits Hard In Myeloma
This article was originally published in The Pink Sheet Daily
Lead investigator for Bristol/AbbVie’s Phase III ELOQUENT trial of elotuzumab in myeloma says PFS curves are reminiscent of PD-1 inhibitors, expects overall survival benefit to be evident soon.
You may also be interested in...
The potential for cancer immunotherapy was the clear takeaway from ASCO 2013. With a lead on the competition, a portfolio with a variety of intriguing mechanisms and many combination trials ongoing, Bristol looks to take immuno-oncology development to the next level.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.